We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 13, 2020

Efficacy and Safety of T-DM1 + Capecitabine vs T-DM1 Alone in Previously Treated ERBB2+ Metastatic Breast Cancer

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial
JAMA Oncol 2020 Jun 25;[EPub Ahead of Print], J Cortés, V Diéras, S Lorenzen, F Montemurro, J Riera-Knorrenschild, P Thuss-Patience, G Allegrini, M De Laurentiis, C Lohrisch, E Oravcová, JM Perez-Garcia, F Ricci, D Sakaeva, R Serpanchy, J Šufliarský, M Vidal, N Irahara, C Wohlfarth, M Aout, K Gelmon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading